{"id":"W2015395716","doi":"10.1007/s10637-013-0024-y","title":"Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer","year":2013,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; University of California, Davis; Celgene; Eli Lilly and Company","keywords":"Pemetrexed; Medicine; Internal medicine; Lung cancer; Oncology; Paclitaxel; Progressive disease; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Phases of clinical research; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005029884,0.0002178449,0.0003597236,0.0002104747,0.00007840226,0.00001427651,0.00008406956,0.0000510788,0.0002292503],"category_scores_gemma":[0.0000671923,0.000169853,0.00007297858,0.000360495,0.00009180768,0.0001843882,0.0000226123,0.0001304519,0.000015851],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005517197,"about_ca_system_score_gemma":0.002139952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002747319,"about_ca_topic_score_gemma":0.0001202854,"domain_scores_codex":[0.9985217,0.00002256387,0.0004213598,0.0003234549,0.0004665033,0.0002443684],"domain_scores_gemma":[0.9989093,0.000083494,0.000244911,0.0002119072,0.0002683577,0.000282027],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1545609,0.08407237,0.3757128,0.003568681,0.004405509,0.0001899388,0.09164745,0.05145025,0.0338498,0.003884114,0.0723802,0.124278],"study_design_scores_gemma":[0.8576228,0.01260427,0.09753645,0.002051744,0.0007287957,0.000002525973,0.0006424536,0.001721243,0.02367296,0.001422346,0.001312381,0.0006820297],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939378,0.0001083078,0.00003085532,0.001893053,0.0001944268,0.002283365,0.0001066827,0.00002322711,0.001422235],"genre_scores_gemma":[0.9925596,0.000009617072,0.003710683,0.001164483,0.0001438292,0.0005422651,0.0002842053,0.00003338246,0.001551934],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7030619,"threshold_uncertainty_score":0.6926406,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01173629540340306,"score_gpt":0.3110161216133163,"score_spread":0.2992798262099132,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}